COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression

Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients

Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma

(RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients